The MRTX Paradox: Analysts Bullish But Forecast -19.51% Fall
June 25, 2018 at 08:29 AM EDT
Analyst ratings can sometimes be complicated, and we here at ETF Channel have noticed a bit of a paradox with Mirati Therapeutics Inc (MRTX). The average 12-month price target for MRTX averaging the work of 6 analysts reveals an average price target of $41.33/share..